About
David Parkinson is acting CEO of Zyngenia, Inc., and a Venture Partner at New Enterprise Associates (NEA). From 2007 until 2012.Parkinson has served as a director of the Company since June 24, 2015 and has been employed full time as the President and Chief Executive Officer of the Company since January 7, 2016. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to 2007, Parkinson was Senior Vice President of Oncology Research and Development at Biogen Idec 2006-2007, Vice President of Oncology Development at Amgen 2003-2006 and Vice President of Global Clinical Oncology Development at Novartis 1997-2003. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as Chief of the Investigational Drug Branch, then as acting Associate Di
Position in the VCSift Database
- • 110 investors hold the Member of the Board of Directors role in VCSift. David Parkinson is one of them.
- • 7,285 investors are based in San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Francisco, US
Contact Information
Find more investors like David
Search Investors